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Abstract: SMYD3 is a member of the SMYD lysine methylase family and plays an important role in
the methylation of various histone and non-histone targets. Aberrant SMYD3 expression contributes
to carcinogenesis and SMYD3 upregulation was proposed as a prognostic marker in various solid
cancers. Here we summarize SMYD3-mediated regulatory mechanisms, which are implicated in the
pathophysiology of cancer, as drivers of distinct oncogenic pathways. We describe SMYD3-dependent
mechanisms affecting cancer progression, highlighting SMYD3 interplay with proteins and RNAs
involved in the regulation of cancer cell proliferation, migration and invasion. We also address the
effectiveness and mechanisms of action for the currently available SMYD3 inhibitors. The findings
analyzed herein demonstrate that a complex network of SMYD3-mediated cytoplasmic and nuclear
interactions promote oncogenesis across different cancer types. These evidences depict SMYD3 as
a modulator of the transcriptional response and of key signaling pathways, orchestrating multiple
oncogenic inputs and ultimately, promoting transcriptional reprogramming and tumor transformation.
Further insights into the oncogenic role of SMYD3 and its targeting of different synergistic oncogenic
signals may be beneficial for effective cancer treatment.
Keywords: SMYD3; KMT; epigenetic inhibitors; lysine methylation
1. Introduction
Lysine Methylation and Cancer
Over the past decades, several enzymes were identified as chromatin writers of epigenetic marks.
Subsequently, novel classes of erasers of these marks have been characterized, as well as of chromatin
readers, which translate these chromatin marks in a functional output [1].
A number of studies and technological advances of recent years have improved our understanding
of one of these histone marks, histone lysine methylation, emphasizing its fundamental role in chromatin
processes, such as transcription, DNA replication and DNA repair, and revealed lysine methylation
involvement in different cellular processes, such as cell fate determination and maintenance, cell
signaling, genome stability and cell proliferation [2]. In particular, these insights have led to the
elucidation of an extensive set of functions for lysine methylases (KMT) that can be associated with
molecular events contributing to tumorigenesis, tumor maintenance and dissemination [3]. For instance,
several events involving chromatin deregulation in cancer have underscored alterations in histone
Cancers 2020, 12, 142; doi:10.3390/cancers12010142 www.mdpi.com/journal/cancers
Cancers 2020, 12, 142 2 of 18
lysine methylation, leading to a modified transcriptional programming of the cancerous cell, thus
sustaining oncogenic transformation [4].
More recently, it was appreciated that non-histone proteins are also targeted by lysine methylase
and demethylase, and that the molecular function of this modification in these targets mirrors what
was previously described for histones, representing a signal for association with effector proteins [5].
Overall, the current interpretation is that lysine methylation plays a similar role in histone and
non-histone substrates, modulating protein–protein and protein–DNA interactions [5,6].
These studies on how KMT affect the chromatin landscape during cancer progression also
recognized that these sets of chromatin factors are novel targets for therapeutic intervention, and set
the ground for the development of epigenetic drugs aimed at blocking their activity and ultimately,
their molecular reprogramming occurring in cancer [7].
Among the numerous lysine methylases, SMYD3 represents an interesting example because it
plays a significant role in cancer progression and invasion, both methylating several non-histone
proteins involved in tumorigenesis and affecting transcriptional regulation.
Here, we aim at drawing together several reports addressing SMYD3 function in cancer, as well
as the diverse activities in which it is involved.
2. SMYD3 Structure
Five members of the SMYD family have been identified (SMYD1–5). Their distinctive features are
the presence of a myeloid-Nervy-DEAF-1 (MYND) domain and a SET domain, which is split in two by
the MYND domain and is followed by a cysteine-rich post-SET portion [8,9]. SMYD1–4 also share the
presence of a degenerate tetratricopeptide repeat (TPR) at the carboxy terminal domain (CTD) [10].
As previously described, for the majority of KMTs, the SET domain of SMYD proteins catalyzes
lysine methylation, but the requirement for broader specific flanking regions neighboring the SET
domain is a distinctive feature of the SMYD family. In human SMYD3, the MYND domain (aa44–93),
a cysteine-rich zinc finger motif, is involved in protein–protein interactions through its charged residues
(Figure 1) [11]. According to other groups, this positively charged region might also serve as a DNA
interaction surface, which promotes methylation activity [9]. The N-terminal region of the protein
encloses a pre-SET domain (aa1–43) called N-SET domain, which acts as an inhibitory region for the
enzymatic activity [12]. In fact, the deletion of the first 34 amino acids results in enhanced methylation
activity [13]. The remaining part of the SET (aa94–242) follows the MYND domain and it is formed by
an intermediate or linker region (I-SET) and the C-SET domain, which contains key residues for the
catalytic activity (Figure 1).
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In S YD3, the TPR-like domain (aa271–428) appears to modulate the association with the MEEVD
peptide within HSP90 and likely many other proteins [10,14]. The HSP90 interaction positively
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regulates SMYD3 in vitro methylation activity, and point mutations in residues that are crucial for
HSP90 association affect SMYD3 cellular compartmentalization (Figure 1) [14].
Moreover, the CTD domain acts with the SET (aa94–242) and post-SET (aa243–270) domains, to
form a deep and narrow substrate-binding pocket, showing that additional regions surrounding the
SET domain are critical for substrate selection and methylase activity [9]. Several residues in the CTD
region, in the SET and the post-SET domains: Y239 [15], F183 [16], C186, E192 [8], I179, V195 [17],
H206 [18], D241 in SET, and D332 in CTD [12] have been identified as crucial for lysine methylation
activity [9] (Figure 1).
SMYD3 crystal structure, either with substrate peptides [17], with a SAM analog [8] or with
sinefungin [11] revealed its two-lobed structure surrounding the substrate binding cleft, situated in
between the two lobes. The pre-SET, SET, MYND and post-SET domains constitute the N-terminal
lobe, while the C-terminal domain contains the TPR region. The N-terminal lobe is crucial for cofactor
binding, while the cleft formed by the two lobes creates a crevice crucial for substrate binding [19].
In addition, the CTD undergoes a hinge-like bending which reduces the clamshell opening and
profiles a small substrate binding cleft [12]. According to this model, the CTD and the MYND domain
may interact, further defining the narrow substrate-binding pocket [20].
Overall, structural analyses provide mechanistic insights into SMYD3 substrate preference, and
its catalytic activity.
3. SMYD3 Levels Are Altered in Cancer
Genetic alterations of several chromatin factors endowed with oncogenic or tumor-suppressor
functions affect cancer initiation and progression [21].
Experimental evidences with tumor biopsies and expression analysis of tumor datasets revealed
that SMYD3 is over-expressed in various forms of cancer, and that higher SMYD3 levels correlate with
a reduced overall survival and worst prognosis [22]. Recently, SMYD3 was suggested as a potential
prognostic biomarker for diagnosis of prostate cancer [23], breast carcinoma (BrCA) [24] and colorectal
cancer (CRC) [25].
In a comprehensive genomic and transcriptomic analysis of 51 human KMTs in a panel of breast
cancer cell lines and primary breast cancer samples, SMYD3 was identified among the eight KMTs
with high-level amplification and most clinical relevance [26]. Interestingly, amongst the 51 KMTs
analyzed, SMYD3 showed the highest level of amplification, and the size of the SMYD3 containing
1q44 amplicon spanned approximately 1.5 Mb in breast cancer [26].
In agreement with the observation that SMYD3 is over-expressed in colorectal cancers, a study
on 117 pairs of CRC and para-tumor tissues showed that the SMYD3 promoter is significantly
hypomethylated in CRC when compared to the para-tumor tissues, suggesting that promoter
hypomethylation may be involved in SMYD3 upregulation in certain types of cancer [25].
A homozygous [[CCGCC]3] variable nucleotide tandem repeat (VNTR) in the SMYD3 promoter
is associated with increased risk of CRC, hepatocellular (HCC), BrCA and esophageal cancer (EC)
cancer in relation to tobacco smoking [27–29]. In contrast, this VNTR genotype does not appear to be
associated with the familial forms of BrCA and HCC cancers [30]. Importantly, the VNTR harbors
a binding site for the transcription factor E2F1, which shows enhanced binding ability in the VNTR
genotypes associated with different forms of cancer [28]. These data suggest that SMYD3 transcription
may be regulated by E2F1 in cancer cells and that the three repeats represent a high-risk allele.
In chronic lymphocytic leukemia (CLL) cells, STAT3 is directly associated with the SMYD3
promoter and favors SMYD3-mediated cell growth both in vivo and in vitro [31]. SMYD3 and
STAT3 were found expressed at high levels in CLL. Interestingly, upregulated SMYD3 significantly
promotes the CLL cells proliferation, while the inhibition of STAT3 activation dramatically reverses
this effect. Furthermore, STAT3 inhibitors that prevent STAT3 phosphorylation also suppress SMYD3
expression [31].
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In gastric cancer cells, Wtn3a stimulation promotes SMYD3 transcript expression, through the
direct recruitment of β-catenin/TCF4 complex in Wnt3a-treated SGC7901 gastric cancer cells [32].
Insights in SMYD3 transcriptional regulation can also be gained by studies on non-cancerous
models, such as in iTreg differentiation. In this system, the Notch and TGFβ pathways induce SMYD3
expression. During the early differentiation stages of iTreg, the Notch and TGFβ pathways induce
SMYD3 expression. During the early differentiation stages of iTreg, Notch signaling favors SMYD3
expression by RBP-Jκ direct recruitment to the SMYD3 promoter [33]. In addition, SMYD3 levels
increase during 48 h of iTreg-skewing condition and TGFβ is the primary inducer of SMYD3, through
the direct association of SMAD3 with the SMYD3 promoter [34]. Nevertheless, TGFβ treatment did
not induce a significant increase in SMYD3 transcript levels in breast cancer epithelial cells [35,36],
suggesting that SMAD3-dependent regulation is context specific.
Besides transcriptional regulation, SMYD3 levels are also regulated by intronic RNA, pre-mRNA
and mRNA-mediated modulation.
For instance, SMYD3 intronic regions recruit the methylase EZH2, thus guiding repressive
complex PRC2 association to the corresponding genomic region of SMYD3, resulting in increased H3K27
tri-methylation at the SMYD3 gene and decreased levels of SMYD3 transcripts. Thus, abnormal increase
in SMYD3 transcripts can be partially counteracted by increased recruitment of EZH2-associated
repressive complexes [36].
The long noncoding RNA SPRIGHTLY (SPRIGHTLY lncRNA) was also identified as an upstream
regulator of the SMYD3 pathway. SPRIGHTLY lncRNA acts as an intranuclear organizing hub
for pre-mRNA molecules and its aberrant expression correlates with a variety of cancers. Lin F et
al. described that this lncRNA interacts with the intronic regions of the SMYD3 pre-mRNA in the
melanoma cancer cell model. Interestingly, hemizygous knockout of SPRIGHTLY by CRISPR/Cas9
in cancer cells significantly decreases SPRIGHTLY lncRNA levels, simultaneously decreasing the
levels of its interacting SMYD3 pre-mRNA molecule and anchorage-independent growth rate of cells.
Remarkably, the rate of in vivo tumor growth in mouse xenografts is also reduced [37].
SMYD3 levels appear to be also modulated by miRs, such as miR124 in cholangiocarcinoma
cells [38] and miR346 in HCC cells [39]. miR124 directly associates with SMYD3 3’UTR and miR124
downregulation in Hepatitis C virus (HCV)-related intrahepatic cholangiocarcinoma (HCV-ICC) is
linked to SMYD3 upregulation. Moreover, the migration and invasion suppressing effects of miR-124
were partially attenuated by SMYD3 over-expression [38].
miR-346 is significantly down-regulated in HCC tissues, in comparison with the non-tumor
controls and is associated with the tumor size and grade. Indeed, miR-346 has a role in suppressing
HCC proliferation. Bioinformatic algorithms and luciferase reporter assays proved that miR-346
directly targets the SMYD3 3’UTR region. Of note, down-regulation of SMYD3 neutralized the
inhibitory effects of miR-346 on HCC proliferation [39].
Although all these reports (Table 1) shed some novel light on the intricate layers contributing to
the regulation of SMYD3 levels, the clinical relevance of SMYD3 over-expression in cancer warrants a
more comprehensive understanding of the underlying molecular mechanisms.
Table 1. Summary of mechanisms regulating SMYD3 levels in cancer.
Molecular Mechanism Cancer Type Effect on SMYD3 Levels Ref.
1q44 ampification Colon cancer cell lines, breastcancer Upregulation [26]
Promoter
hypomethylation Colon cancer Upregulation [25]
[(CCGCC)3] VNTR Colon, hepatic, breast cancer Upregulation [27–30]
STAT3-mediated
regulation
Chronic lymphocytic leukemia
cell lines Upregulation [31]
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Table 1. Cont.
Molecular Mechanism Cancer Type Effect on SMYD3 Levels Ref.
Wnt-mediated regulation Gastric cancer cell lines Upregulation [32]
PRC2 association to
SMYD3 intronic regions Colon cancer cell lines Downregulation [36]
SPRIGHTLY lncRNA Melanoma cancer cell lines Upregulation [37]
miR124 downregulation HCV-related intrahepaticcholangiocarcinoma cell lines Upregulation [38]
miR346 downregulation Hepatocellular cancer cell lines Upregulation [39]
4. SMYD3-Dependent Mechanisms Affecting Cancer Progression
SMYD3 was initially described as a H3K4 methylase, involved in cancer cell proliferation [15].
However, in vitro assays with bacterially expressed SMYD3 protein revealed that SMYD3 does not
display methylation activity on histone H3, neither on recombinant histone H3 nor in a nucleosomal
context. Instead, in vitro methylation studies have shown that histone H4K5 is the preferred histone
substrate [16,40]. However, the relevance of SMYD3-mediated H4K5 methylation is not well defined
in vivo. Despite these in vitro evidences, SMYD3 knockdown has been frequently associated with a
decrease in H3K4 methylation in cell culture studies. Nevertheless, SMYD3 mediated impact on H3K4
methylation may represent an indirect effect, resulting from decreased transcription of the target gene.
Alternatively, SMYD3 may require other uncharacterized interacting proteins to direct its enzymatic
activity on histone H3K4.
Furthermore, SMYD3 was also reported to dimethylate the histone variant H2A.Z.1 at lysine 101.
The colocalization of SMYD3 and H2A.Z.1K101me2 at the promoter of cyclin A1 promotes its expression
and G1-S progression in BrCA cells [41]. In agreement with these data, and with the SMYD3 role
in regulating the cell cycle related gene, we have shown that SMYD3 is required for proper S phase
completion in different types of tumor cells (CRC, lung, pancreatic, ovarian and prostate cancer)
(Table 2) [40].
Table 2. Summary of SMYD3 methylation targets.
SMYD3 Methylation
Target Cancer Cell Line Effect Ref.
Histone H4-K5 HeLa and MEFs Unknown [16]
Histone H2A.Z.1-K101 MCF7 and TD47 Promotes transcription ofproliferation related genes [41]
VEGFR1-K831 HEK293 over-expressingSMYD3
Enhancer of VEGFR1 kinase
activity [42]
MAP3K2-260 LKR10, HEK293over-expressing SMYD3
Methylation-dependent
modulation of PP2A/MAP3K2
interaction
[43]
AKT1-K14
SW480, MDA-MB-231
HEK293 and HeLa
over-expressing SMYD3
Enhancer of AKT activition [44]
HER2-K175 none Enhancer of HER2 activation [45]
More recently, it has become clear that SMYD3 promotes oncogenesis through very diverse
pathways, ascribed, on the one hand, to its enzymatic activities on histone and non-histone proteins,
and on the other hand, to transcriptional related functions. In fact, SMYD3 is localized in the cytoplasm
in many tumor cells [15,43], but a fraction of the protein is also found in the nucleus of several cancer
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cells [18,35]. These pieces of evidence suggest that SMYD3 may play different roles in distinct tumors,
and that its cellular localization may be tightly regulated.
In the following sections, we will delve deeper into the diverse SMYD3-mediated functions and
their role in cancer progression.
4.1. SMYD3 Methylates Non-Histone Proteins
SMYD3 methylation-dependent functions include its ability to methylate non-histone proteins,
which are involved in the cancer cell survival and proliferation.
Specifically, SMYD3 interacts with and methylates cytoplasmic proteins, such as vascular
endothelial growth factor receptor 1 (VEGFR1). The methylation of K831 potentiates angiogenesis
through ligand dependent autophosphorylation and increases kinase activity [42]. In lung and
pancreatic cancers, SMYD3 localization is exclusive to the cytoplasm and it potentiates RAS/ERK
signaling through the methylation of the MAP3K2 kinase, by preventing its interaction with a negative
regulator, namely the PP2A phosphatase complex [43]. Accordingly we found that SMYD3 genetic
knockdown correlated with reduced MEK–ERK signaling in CRC models [40]. SMYD3 over-expression
has been described especially in cancer types carrying K-Ras mutations and since the k-Ras mutations
occur in more than a half of human cancers, the link to SMYD3 is clinically very relevant [46,47].
Besides MAP3K2, SMYD3 was reported to methylate lysine 14 of the serine/threonine–protein
kinase AKT1, a key mediator of a signaling pathway that governs various cellular processes regulating
cell growth, survival, glucose metabolism, genome stability and neovascularization. Interestingly,
mutation of lysine 14 diminishes the plasma membrane accumulation of AKT1. In addition, cancer
cells overexpressing lysine 14-substituted AKT1 shows decreased growth rate in comparison to those
overexpressing wild-type AKT1. Overall, these data imply that SMYD3-mediated methylation of
AKT1 at lysine 14 is essential for AKT1 activation and suggest that the inhibition of this methylation
pathway may be a promising strategy to develop anti-cancer drugs [44,45].
In breast cancer cells, SMYD3 was found to tri-methylate the HER2 protein at lysine 175, and
this post-translational modification (PTM) stimulates its activation through autophosphorylation [45].
The SMYD3/HER2 link is clinically relevant because of the abnormal HER2 activation involved in
development and progression of various types of cancers: namely, HER2 amplification is observed in
18–25% of BrCA and correlates with poor prognosis (Table 2) [48].
4.2. SMYD3 Modulates Pathways Involved in Cancer Cell Proliferation
Many studies have advocated a role for SMYD3 in the regulation of cancer cell proliferation.
Interestingly, SMYD3 knockdown by RNAi has been reported to affect cell proliferation in HCC,
BrCA, cervical cancer, EC, CRC, lung adenocarcinoma and KRAS-driven pancreatic cancer cell
lines [15,16,43,49–57]. Conversely, SMYD3 overexpression in NIH-3T3 cells has been shown to promote
cell transformation by enhancing cell growth rate [15,53].
In contrast to the above findings, a recent study has shown that SMYD3 is not required for
autonomous cancer cell proliferation in vitro. By means of small molecule inhibitors and CRISPR/Cas9
mutagenesis, Thomenius et al. reported the lack of proliferative effects in 240 and 313 cancer cell lines,
respectively [58]. However, this study tested the in vitro effect of SMYD3 expression and/or activity
impairment without taking into account the roles of tumor heterogeneity and the microenvironment.
Our previous report about SMYD3 function in tumors revealed a considerable effect on cell
cycle progression with a significant increase in the S phase population, following SMYD3 genetic and
pharmacological ablation. Indeed, cancer cells treated with the SMYD3 inhibitor BCI-121 accumulated
in the S phase of the cell cycle, suggesting that SMYD3 might be required for proper cell cycle
progression through the S/G2 boundary [40].
In agreement with our findings, Jiang Y et al. showed that SMYD3 inhibition with the
small-molecule BCI-121 leads to S phase arrest and increases the ovarian cancer cell apoptosis
rate. By using a gene expression array, they found several cell cycle and apoptotic modulated genes
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upon SMYD3 knockdown, such as an upregulation of the cyclin-dependent kinase (CDK) inhibitors
CDKN2A [p16INK4], CDKN2B [p15INK4B], CDKN3 and CDC25A, which may be responsible for the
S phase arrest. In addition, the mis-regulation of the apoptotic-related genes CD40LG and BIRC3,
known as apoptotic related genes, was proposed to explain the increased cell apoptosis rate following
SMYD3 silencing [59]. Moreover, SMYD3 regulates the transcription of hTERT, a major control factor
of tumor cell immortalization, through its binding to two responsive sites on the promoter of hTERT.
SMYD3 deficient tumor cells lose occupancy of the hTERT promoter by the transcription factors c-MYC
and Sp1, leading to repression of telomerase activity [60].
SMYD3 activity was also correlated to the expression of RIZ1, a tumor suppressor protein silenced
in a variety of cancers such as liver [61], breast [62], colon [63], gastric [64] and glioma [65] and whose
expression is linked to G2/M arrest and induction of apoptosis in cancer cells [66]. Interestingly, SMYD3
over-expression in HCC and esophageal squamous cells carcinoma (ESCC) was associated with RIZ1
hypermethylation and mRNA down regulation [50,51].
In MDA-MB-231 BrCA cells, SMYD3 knockdown induces G0/G1-phase arrest [67]. Conversely,
in MGC-803 gastric cancer cells, SMYD3 down-regulation induces G2/M-phase arrest. Furthermore,
it has been demonstrated that the absence of SMYD3 could halt cells in the G2/M phase via the
ATM-CHK2/p53-Cdc25C pathway [57].
Taken together, these opposing data about the effect of SMYD3 on different stages of the cell cycle
suggest that SMYD3 might play different roles at different stages of the cell-cycle and impact different
types of carcinomas in distinct ways.
Overall, these data suggest that the combination of different SMYD3-mediated regulatory loops
may affect distinct facets of proliferation in different tumor cells.
4.3. SMYD3 Promotes Tumor Cell Migration
Besides cell proliferation, SMYD3 has been linked to the increased migration and invasion ability
of cancer cells in several tumor cell lines. Notably, SMYD3 was also identified as a signature gene in
metastatic pancreatic cancer cells [68].
Cell invasion and metastatic spread are linked to a loss of epithelial factors, disruption of cell
polarity and increase in mesenchymal protein expression, a process known as epithelial–mesenchymal
transition (EMT) [69]. Besides their involvement in secondary tumor formation, EMT signature genes
have recently been linked to cancer initiation and defined as a hallmark of cancer stem cells [70].
While a deep characterization of SMYD3 functions in different cancer stem cells is still lacking,
initial findings in gastric carcinoma stem cells show that SMYD3 controls Wnt induced activation of
the ASCL2 gene, a master regulator of stem cell maintenance. SMYD3 is recruited to the chromatin
regulatory region of ASCL2 and positively regulates its transcription. Remarkably, SMYD3 knockdown
inhibits tumor sphere growth and the number of sphere-initiating cells. In vitro, SMYD3 depletion
leads to decreased anchorage independent growth, and xenografts formed by SMYD3-depleted tumor
cells results in smaller tumor nodules [32].
These studies represent an initial elucidation of the SMYD3 role in cancer stem cells and may
pave the way to future investigations on the role of SMYD3 in the early stages of tumor formation
and dissemination.
Likewise, SMYD3 over-expressing HCC cells injected in the tail vein of nude mice gave rise to a
significantly higher number of metastatic lung foci when compared to control cells. In HCC, SMYD3
positive expression is significantly linked to hepatitis B virus (HBV) infection, microvascular invasion,
poor tumor differentiation, high TNM stage, and a worse prognosis, suggesting that SMYD3 plays an
important role in HCC progression. In cultured HCC cells, SMYD3 co-occupies the SNAI2 promoter
in collaboration with the ANKHD1 protein, promoting invasion and metastasis through the SNAIL2
pathway [71]. In addition, invasion of tumors obtained from SMYD3 knocked-down KYSE150 ECC
cells was much lower than that of control cells [72].
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Among different methylases, SMYD3 is upregulated in spheroids of epithelial ovarian cancer
(EOC) compared to monolayer cells, and SMYD3 depleted spheroids as well as spheroids treated
with the SMYD3 inhibitor BCI-121 exhibited a decreased invasion and adhesion potential, through
downregulation of integrin family members. Moreover, SMYD3 knockdown inhibited tumor metastasis
and reduced ascites volume in xenograft models [73].
SMYD3 also regulates transcription of EZR and LOXL2 genes by direct recruitment to their
promoter regions, thus sustaining proliferative, migration and invasion signaling in esophageal cancer
cells [56]. Importantly, LOXL2 has been linked to transformation events in different types of tumors.
Increased LOXL2 expression promotes gastric cancer metastasis through Src/FAK kinase, tumor
progression via Snail/ E-cadherin and BrCA metastasis by activating ErbB2 via reactive oxygen species
(ROS) production [74–76].
SMYD3 also transcriptionally regulates c-Met, a key proto-oncogene encoding a receptor tyrosine
kinase [55]. c-Met is activated by the hepatocyte growth factor ligand and its overstimulation is critical
in various properties of cancer cells, including proliferation and EMT induction [77]. Perturbation of
SMYD3 expression affected c-Met transactivation and inhibited invasiveness of liver and BrCA cells
in vitro, with mutational analysis revealing the functional importance of two SMYD3 binding sites on
the c-Met promoter [55].
In prostate cancer, SMYD3 elicits its oncogenic activity by stimulating androgen receptor (AR)
transcription. AR is the central signaling pathway in normal growth of the prostate gland and is
frequently overexpressed during prostate cancer progression. Of note, genetic depletion of SMYD3
interferes with the activation of proliferative signals and inhibits colony formation, cell migration,
invasion and xenograft tumor formation. The molecular mechanism at the basis of these observations
lies in the presence of two functional SMYD3-binding motifs in the AR promoter region [78].
In addition, SMYD3 is over-expressed in HBx-induced HCC, and it promotes invasion and
metastasis through transcriptional activation of a novel oncogenic lncRNA, lncIHC [79].
Hence, SMYD3 orchestrates cancer cells proliferation and migration influencing oncogenes, tumor
suppressors, cell cycle related-genes and EMT factors, thus promoting tumorigenesis in different
interconnected ways.
5. SMYD3 Functions In Vivo
SMYD3 is ubiquitously expressed in adult tissues and its transcript is detectable during
embryogenesis [80,81]. While a thorough characterization of the SMYD3 role in normal tissue is still
missing, a few reports have identified a role for SMYD3 in early embryonic lineage commitment and
peri-implantation development, through the modulation of lineage-specific genes [82,83]. In zebrafish,
SMYD3 is required for normal cardiac and muscle development, and SMYD3 knockdown by a
morpholino approach results in embryos with pericardial edema and curved trunk [84]. The latter
finding is particularly interesting, since other SMYD family members play a prominent role in
myogenesis [85]. In agreement with these data, SMYD3 transcriptionally regulates myostatin and
c-Met levels in mouse myotubes, thus modulating the myotubes diameter in vitro, as well as the
skeletal muscle mass in vivo [86]. In addition, a recent report shows that SMYD3 modulates myoblast
differentiation, through Myogenin transcriptional regulation [87]. Despite this initial characterization of
SMYD3 functions in physiological conditions, SMYD3-KO (knockout) mice develop normally, and are
viable and fertile [18,43], suggesting that in normal conditions, SMYD3 activities may be compensated
for by other factors, for instance other SMYD family members. Although Smyd3-KO animals are
healthy, the number of actively proliferating colon crypt bottom cells was reduced compared to that
which was observed in control mice, and colon cells expressed significantly reduced transcript levels of
CcnA3, CcnD1 and CcnE1. These in vivo findings suggest that SMYD3 activity is critical in pathways
regulating proliferation and survival abilities of normal cells. Furthermore, high expression levels of
SMYD3 in tumors is linked to specific functions acquired in tumorigenesis, wherein its key role in cell
proliferation is further amplified.
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Conversely, studies performed with these SMYD3 knockout mouse models have reported a
crucial and specific involvement of SMYD3 in oncogenesis (Table 3). Mazur et al. showed that
SMYD3 knockdown reduces tumorigenesis induced by KRAS mutation in the pancreas and lung [43].
Likewise, Sarris et al. demonstrated that SMYD3 is required for chemically induced liver and colon
carcinogenesis. In particular, the latter report showed that in a SMYD3 total-body knockout model of
diethylnitrosamine (DEN)-induced liver cancer, SMYD3 did not affect cell death and/or associated acute
or chronic inflammation, but it was required for cell proliferation. In chemically induced liver tumors,
SMYD3 is recruited to the promoters of cell cycle related genes (CcnA2, CcnE1, CcnD1, Pcna, and Igfbp1).
Sarris et al. demonstrated how the expression of cell cycle related genes is marginally affected in the
livers or colons of carcinogen-treated Smyd3-KO mice, as opposed to their significant upregulation in
treated wild type animals, implicating a requirement for SMYD3 in carcinogenesis. ChIP- and RNA-Seq
assays showed that SMYD3 directly regulates Myc and Ctnnb1 oncogenes, as well as components of the
IL6-Jak-Stat3 oncogenic cascade and other cell proliferation and cancer-related genes, in liver and colon
carcinogenesis [18]. Notably, 66% of SMYD3 binding sites were also occupied by RNA-PolI, which is
able to interact with SMYD3 in immunoprecipitation assays [15,18,86]. These findings suggest that
SMYD3 recruitment to chromatin regulatory regions occurs through the association with the RNA PolII
complex. In addition, SMYD3 occupancy in proximity to the transcriptional start site (TSS) matches the
H3K4me3 peak distribution at TSS [18]. Moreover, in vitro data show that SMYD3 CTD can interact
with a H3K4me3 peptide, suggesting that this may provide additional means of recruitment to the
chromatin. SMYD3 was initially reported to be associated with the CCTCCC DNA sequence [15].
This evidence was confirmed by direct search of the sequence motifs underlying the SMYD3 binding
locations [18]. Furthermore, an unbiased in vivo search revealed novel consensus sequences enriched
in SMYD3 occupied regions. Overall, this genome-wide approach established that SMYD3 occupies
regulatory regions of key regulators involved in proliferation, and suggested that SMYD3 recruitment
to the chromatin can be mediated by its interplay with interactors, e.g., RNAPolII, H3K4me3 and
putative sequence-specific DNA binding proteins. Indeed, we can imagine a scenario where SMYD3
may act as a component of multi-enzymatic complexes involved in different proliferative pathways
deregulated in tumors.
Table 3. Summary of SMYD3 roles in cancer in vivo.
Model Cancer Type Impact of SMYD3IncreasedLevels Ref.
Mouse experimental
model
pancreatic ductal and
lung adenocarcinoma
experimental models
Increase in MAP kinase
signaling in K-Ras mutated
cancers
[43]
Mouse experimental
model
chemically induced liver
and colon
Transcriptional up-regulation of
proliferation and EMT genes [18]
Human cancer Breast Reduced DFS in claudin-lowpatients [35]
Human cancer Hepatocellularcarcinomas
Positive correlation with HCC
development [18]
Human cancer Lung Shorter progression free survival [22]
Human cancer Liver Shorter overall andprogression free survival [22]
Human cancer ESCC, ovarian, colon,glioma Shorter overall survival [22,25,56,59,88]
This hypothesis is supported by different studies where SMYD3 has been found to interact
with factors belonging to complexes that influence proliferative pathways, in cancer cell extracts.
For instance, SMYD3 associates with the heat shock protein 90 (HSP90) and loss of this interaction results
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in impairment of the ability of SMYD3 to bind to the chromatin and to promote cell proliferation [14].
The PC4 coactivator is another component of the transcriptional machinery that interacts with SMYD3,
stabilizing its chromatin occupancy and promoting the activation of cell proliferation and invasion.
SMYD3 functionally cooperates with PC4, by co-localizing at target genes downstream of proliferative
signals [89]. Furthermore, SMYD3 has been shown to interact with transcription factors involved
in cancer, such as the estrogen receptor (ER). The ER–SMYD3 complex is recruited to the regulatory
regions of ER target genes and potentiates ER-dependent gene transcription (e.g., GREB1, CTSD, TFF1)
in the estrogen signaling pathway (Figure 1) [90,91].
In vivo, SMYD3 directly regulates key EMT inducers and regulators, in DEN-induced liver tumors
and DEN-induced liver tumors in SMYD3-KO mice do not express key EMT transcripts, such as MMP2,
MMP14, Vimentin, Sox4, Zeb1, SNAI1 and Fn1, pointing to the direct role of SMYD3 in transcriptional
activation [18] (Table 3).
Our data confirmed these results in an in vitro model where EMT was induced by TGFβ treatment,
in BrCA cells. SMYD3 was recruited to mesenchymal gene regulatory regions (e.g., MMP9, Sox9, SNAI1,
Vimentin) during TGFβ-induced EMT and SMYD3 co-occupancy with SMAD3 at these mesenchymal
genes promoted transcriptional regulation. SMYD3 CTD interacts with SMAD3, and this region is
crucial for mesenchymal genes regulation. Genetic knockdown or pharmacological blockade with
the BC1-121 inhibitor prevents mesenchymal markers transcriptional upregulation and impairs the
migration ability of TGFβ treated cells. Notably, treatment with the SMYD3 inhibitor BCI-121 reduces
the invasive ability of mesenchymal breast cancer cell in vivo, in a zebrafish xenograft model [35].
Remarkably, methylation activity may be dispensable for SMYD3-mediated transcriptional
regulation on certain target genes. For instance, Sarris et al. showed that a methylation-deficient
SMYD3 mutant (H206G) transactivates the Igfbp1, Pcna, Sox4, Myc promoters in the same way as
the methylation intact protein [18]. These findings are in agreement with our data, showing that
SMYD3-mediated regulation of mesenchymal genes is also methylation independent, in TGFβ treated
BrCA cells [35].
Analysis of the clinical dataset supports the results obtained in experimental models. For instance,
the liver and breast human cancer sample dataset from the “The Cancer Genome Atlas” (TCGA)
revealed that SMYD3 transcript levels correlate with expression of key proliferation [18] and EMT
genes [18,35]. In addition, SMYD3 expression was positively associated, respectively, with the
metalloproteinases MMP-2 and MMP-9 expression in pancreatic and gastric cancer tissues [92,93].
Remarkably, SMYD3 higher expression levels correlate with a less favorable metastasis-free
survival in liver and HCC, as well as in the claudin-low BrCA subtype [18,22,35,71].
In ESCC, glioma, lung and ovarian cancers patients carrying low SMYD3-expressing tumors,
overall survival [OS] is significantly longer than in those with high SMYD3-expressed cancers [22,59,88].
In ESCC, SMYD3 over-expression is also related to lymph node metastasis [56] (Table 3).
Overall, these data hint for a clinical role in SMYD3 as a prognostic factor in different forms
of cancer.
6. Design and Testing of SMYD3 Inhibitors
The above scenario depicts how a complex network of cytoplasmic and nuclear interactions
contribute to branch out SMYD3 oncogenic action across different cancer types. These data, together
with the lack of obvious defects upon SMYD3 knockout in healthy tissues (www.sanger.ac.uk/
mouseportal/search?query=smyd3) and its widespread overexpression in many cancers justify the
ongoing efforts in developing inhibitors blocking SMYD3 functions, as anti-cancer therapy [94].
Selective small molecules inhibitors have been designed as a tool to better characterize
SMYD3 functions, and as a starting point to develop targeted therapeutic approaches. To date,
few SMYD3-selective inhibitors have been described: BCI-121, EPZ031686, EPZ030456, GSK2807,
EPZ02862, and tetrahydroacridine compounds as a newly designed class of irreversible inhibitors
(Table 4).
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Table 4. Summary of SMYD3 inhibitors.
Inhibitor Mode of Action In Vivo Tested Effect on Cell Models Ref.
BCI-121 Substrate competitive Yes
Decreased proliferation
rate of colon cancer HT29
and HCT116 cell lines
[35,40]
EPZ031686
Substrate
non-competitive;
SAM mixed-type
Yes - [95]
EPZ030456
Substrate
non-competitive;
SAM mixed-type
No - [95]
GSK2807 SAM competitive No - [96]
EPZ02862
Substrate
non-competitive;
SAM mixed-type
Yes
No effect on cell
proliferation in lung
cancer cell lines
[58]
Tetrahydroacridine
compounds
covalent modification
of SMYD3 No
Decreased proliferation
of HepG2 cells [97]
BCI-121 is the first described SMYD3 inhibitor, which was identified through in silico
high-throughput screening of a database. BCI-121 is associated with SMYD3 in the channel connecting
the lysine and the cofactor pocket. In vitro methylation assays showed that BCI-121 blocked histone H4
methylation, blocking substrate interaction. BCI-121 treatment significantly decreased the proliferation
rate of colon cancer HT29 and HCT116 cell lines, by arresting the cell cycle at S-phase.
BCI-121 binds to the histone-binding site of SMYD3 and it thus inhibits SMYD3/histone H4
interaction, in HCT116 and OVCAR-3 cancer cell lines. The SMYD3 residues interacting with BCI-121
through hydrogen bonds are S202 and Y239 in the substrate-binding pocket of SMYD3 [40]. Notably,
BCI-121 administration both prevents SMYD3 enzymatic activity and SMYD3 recruitment to the
chromatin of regulatory regions proliferation [35,40]. In different colon, pancreatic, ovarian and lung
cancer cell lines, BCI-121 significantly reduced transcript levels of the SMYD3 target genes c-Met, TERT,
WNT10b and CDK2.
GSK2807 was designed mimicking a portion of both SAH and the SMYD3 substrate MAP3K2
by blocking substrate recognition, and is a SMYD3-selective inhibitor that inhibits SMYD3 activity at
IC50 value of 130 nM. Owing to the poor membrane permeability, GSK2807 cannot be used in in vivo
studies. Nevertheless, it represents a powerful tool to gain insight into SMYD3 catalytic and kinetic
mechanisms [96].
EPZ031686 and EPZ030456 were the first potent and selective SMYD3 inhibitors with nanomolar
activity available for in vitro and cellular assays. EPZ031686 is a noncompetitive inhibitor for SAM
and the MAP3K2 substrate, while EPZ030456 showed mixed type inhibition with respect to SAM, and
noncompetitive inhibition with respect to MAP3K2. EPZ031686 also displayed good bioavailability in
mice, making it a suitable compound for in vivo studies [95].
EPZ028862 is an isoxazole sulfonamide inhibitor, which displays potency similar to EPZ031686 in
biochemical and cellular assays, and it also shows physicochemical properties that make it suitable for
in vivo studies. Nevertheless, this inhibitor does not have any effect on cell proliferation in lung cancer
cell lines with and without KRAS mutations, up to a concentration of 25 µM [58].
A novel class of tetrahydroacridine compounds were recently developed that block SMYD3
activity through a covalent mechanism of action. These compounds covalently modify SMYD3 via a
nucleophilic aromatic substitution reaction. These molecules represent potent SMYD3 inhibitors, are
chemically less reactive than classical inhibitors, and were shown to decrease cell growth in HepG2
cells. In addition, they were able to block MAP3K2 methylation in HepG2 cells [97].
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Future preclinical work is warranted to show the impact of SMYD3 inhibitors treatment in tumor
formation and metastasis, in mice.
7. Conclusions and Future Directions
SMYD3 is over-expressed in several cancer types and represents a promising target to treat
different malignancies. Several pathways known to be altered in tumors (e.g., beta catenin, TGFβ,
STAT3) can augment SMYD3 protein levels in certain models. A more comprehensive understanding
of the different mechanisms leading to SMYD3 upregulation is warranted, to define tumor-specific
mechanisms resulting in SMYD3 over-expression (Figure 2).
SMYD3 appears to promote cancer in a kaleidoscopic manner, reprogramming both the
transcriptional response and modulating signaling pathways, thus orchestrating different oncogenic
inputs, which synergize towards tumor transformation. Likewise, SMYD3 mechanisms of action are also
variegated, spanning from transcriptional regulation, which can be HMT- and non-HMT-dependent,
to the PTM of proteins that is inherently HMT-dependent but can target both histone and non-histone
proteins (Figure 2). Overall, these intricate regulatory networks, affecting both transcription and
signaling transduction, synergize to accelerate oncogenesis, essentially through increased cell
proliferation and promoting cell migration (Figure 2).
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Figure 2. SMYD3-mediated activities that promote oncogenesis. SMYD3 is upregulated in cancer,
where it promotes the activation of oncogenic pathways through two main functions, transcriptional
activation of genes involved in cell proliferation and epithelial–mesenchymal transition (EMT), and
through methylation of non-histone proteins, particularly involved in cell signaling, and resulting in
increased cell growth and cell migration.
Future studies with a proteome-wide approach will lead to the identification of still unknown
non-histone targets and will reveal further insights into the SMYD3-regulated signaling pathways, thus
uncovering novel regulatory mechanisms. For instance, novel insights into SMYD3 post-translation
modifications may also modulate its function.
These findings, when combined with additional biochemical, structural and in vivo approaches,
will pave the way for the design of novel inhibitors, in the search for effective small molecules targeting
SMYD3 in cancer patients.
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